These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27480904)

  • 21. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.
    Lentz SR; Rangarajan S; Karim FA; Andersen PD; Arkhammar P; Rosu G; Mahlangu J
    Blood Coagul Fibrinolysis; 2017 Apr; 28(3):224-229. PubMed ID: 27427786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel products for haemostasis.
    Shima M; Hermans C; de Moerloose P
    Haemophilia; 2014 May; 20 Suppl 4():29-35. PubMed ID: 24762272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma-derived factors VIIa and X mixtures (Byclot
    Ochi S; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant activated factor VII: 30 years of research and innovation.
    Hedner U
    Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
    Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
    Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
    Berntorp E
    Haemophilia; 2009 Jan; 15(1):3-10. PubMed ID: 19016901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
    Polyanskaya T; Zorenko V; Karpov E; Sampiev M; Mishin G; Vasiliev D
    Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry.
    Ma AD; Kessler CM; Al-Mondhiry HA; Gut RZ; Cooper DL
    Haemophilia; 2016 Jan; 22(1):e18-24. PubMed ID: 26551409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
    Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
    Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity.
    Mahlangu J; Paz P; Hardtke M; Aswad F; Schroeder J
    Haemophilia; 2016 Nov; 22(6):873-879. PubMed ID: 27501279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
    Pipe SW; Hermans C; Chitlur M; Carcao M; Castaman G; Davis JA; Ducore J; Dunn AL; Escobar M; Journeycake J; Khan O; Mahlangu J; Meeks SL; Mitha IH; Négrier C; Nowak-Göttl U; Recht M; Chrisentery-Singleton T; Stasyshyn O; Vilchevska KV; Martinez LV; Wang M; Windyga J; Young G; Alexander WA; Bonzo D; Macie C; Mitchell IS; Sauty E; Wilkinson TA; Shapiro AD
    Haemophilia; 2022 Jul; 28(4):548-556. PubMed ID: 35475308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P; Klementz G
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.